



THIRD-QUARTER 2022 RESULTS

TOTAL COMPANY

\$10.4B

SALES
WORLDWIDE

+1.3%¹

ON AN
ORGANIC BASIS*

\$1.15²

ADJUSTED DILUTED EPS

RAISING FULL-YEAR 2022 EPS GUIDANCE

\$5.17 to \$5.23³

Adjusted Diluted EPS

BUSINESS HIGHLIGHTS

STAYING AHEAD OF VIRAL THREATS

- ▶ U.S. FDA Emergency Use Authorization for Monkeypox PCR test used with Alinity[®] m System
- ▶ The Abbott Pandemic Defense Coalition, a first-of-its-kind scientific and public health partnership, is dedicated to the early detection of and rapid response to viral threats



INNOVATING FOR PATIENTS AND DOCTORS

- ▶ European launch of Amplatzer[™] Talisman[™] PFO Occlusion System
- ▶ System treats people with a patent foramen ovale (PFO) — a hole in the heart that doesn't close following birth — who have experienced a stroke and are at risk of having another



BUSINESS UNIT SALES



\$3.6B

MEDICAL DEVICES



\$3.7B

DIAGNOSTICS



\$1.3B

ESTABLISHED
PHARMACEUTICALS




\$1.8B

NUTRITION

UNITING HEALTH AND TECH IN DIABETES CARE

- ▶ New data show FreeStyle Libre[®]** system reduces diabetes-related hospitalizations for people with Type 2 diabetes on once-daily insulin therapy⁴
- ▶ U.S. launch of FreeStyle Libre 3 system, including the world's smallest and thinnest⁵ wearable sensor



FreeStyle Libre 3
Continuous glucose
monitoring system

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Oct. 19, 2022, available at www.abbottinvestor.com.
**Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

1. On a GAAP basis, third-quarter Abbott sales decreased 4.7%. 2. Third-quarter GAAP diluted EPS was \$0.81. 3. Abbott is raising its projected full-year 2022 diluted earnings per share under GAAP to \$3.75 to \$3.81. Abbott forecasts specified items for the full-year 2022 of \$1.42 per share primarily related to intangible amortization, costs related to a voluntary recall, asset impairments, expenses associated with acquisitions, restructurings and cost reduction initiatives and other net expenses. Excluding specified items, Abbott is raising its projected adjusted diluted earnings per share to \$5.17 to \$5.23 for the full-year 2022. 4. Geraci B, Roussel R, Riveline JP, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre[®] system initiation in people with type 2 diabetes on basal insulin therapy in France. Presented at EADV, 20-22 September 2022, Stockholm, Sweden. 5. Among patient-applied sensors.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.